Hep-Art is managed by Eric van der Aa (CEO), Robert Chamuleau (CSO) and Jan Apers (CFO). Their individual strengths are combined to form a committed management team with a shared vision.
Eric M. van der Aa, PhD (CEO)
Eric has been working in de research oriented pharmaceutical and biotechnology industry for more than 17 years. Next to his responsibilities as CEO of Hep-Art as of 1 June 2012, Eric is currently also owner and statutory director of Aa Technology transfer BV and Chief Business Officer of Pantarhei Bioscience BV. Eric graduated in Biomedical Sciences at the University of Nijmegen, completed his PhD at the Department of Pharmacology of this university and finalized the Postdoctoral Program Toxicology. Following his academic career he was employed at NV Organon as Research Fellow Toxicology and as Licensing Manager for the Research Departments. After his period at Organon he became Statutory Management Team member of Amsterdam Molecular Therapeutics BV (AMT) as Executive Vice President Business Development. Following AMT he founded and directed AMCAS BV. Eric is currently also Board Member of the Dutch Biotechnology Society: Biofarmind.
Robert A.F.M. Chamuleau, MD, PhD (CSO)
Dr. Chamuleau, is a hepatologist at the Academic Medical Center Amsterdam and an associate professor at the University of Amsterdam. He supervised the development of the AMC-BAL and is responsible for the current R&D as well as the coordination of the clinical trial. Dr. Chamuleau is recognized as a leading scientist in the field of bio-artificial liver devices and has a strong international network.